Image credits: Unsplash
Weekly Roundups

Raising Awareness on Food Labels: The Week in Health

By Antonio Gozain | Thu, 11/10/2022 - 10:00

The Partnership for Food Security protested in front of the Supreme Court (SCJN) to defend a much-discussed law that makes labels on food packaging mandatory. The NOM-051-SCFI/SSA1-2010 norm on labeling for prepackaged non-alcoholic foods and beverages was published on March 27, 2020, and was enforced on Oct. 1, 2020, followed by sanctions for non-compliance on Nov. 30. SCJN has received legal protection requests against the modifications to labeling from companies and will rule on the matter shortly.

Desde el Corazón del Fruto spearheaded the campaign against octagon-shaped labels that warn of harmful contents of these products. According to the request, this regulation “violates rights to equality and legal certainty, since not all food products are required to carry the labels, which constitutes an act of discrimination and harms the rights to work and free competition.” Similar requests have since been filed by other companies.


Ready? This is the Week in Health!


UK Approves Pfizer, BioNTech’s Booster Targeting Omicron BA.4, BA.5 Sub-Variants

The Medicines and Healthcare products Regulatory Agency (MHRA), UK’s health regulator, approved the country’s first two-pronged COVID-19 booster targeting the Omicron BA.4 and BA.5 sub-variants. The vaccine from Pfizer and partner BioNTech was approved for people of 12 years of age and older.

Eli Lilly to Pay US$176.5 Million After Migraine Drug Patent Trial

US company Eli Lilly must pay Israeli Teva Pharmaceuticals International US$176.5 million after a Boston federal court jury determined its drug Emgality infringed three Teva patents. Both companies’ drugs treat migraines by employing antibodies to inhibit headache-causing peptides.

Experimental Model Identifies Malignant Cells that Cause Colon Cancer

Researchers at the Spanish Institute for Biomedical Research (IRB) in Barcelona identified the cells responsible for relapse in colon cancer and the reappearance of cancer in other organs after removal of a primary tumor, reported EFE. The finding, published on Nov. 9, 2022 on the Nature journal, shows that early immunotherapy prior to surgery can eliminate these cells before they initiate metastasis and thus prevent relapses in the disease.

FDA Staff Flags Uncertainties on Veru’s COVID-19 drug

Staff reviewers at the US Food and Drug Administration (FDA) identified “several uncertainties” around Veru Inc’s data for its experimental COVID-19 drug but did not raise any new concerns, sending its shares surging 52 percent, reported Reuters.

View From the Top

Do not miss this week’s interviews!

Photo by:   Unsplash
Antonio Gozain Antonio Gozain Senior Journalist and Industry Analyst